Longeveron vs Medicinova
Longeveron is the larger business, with $1.2m of revenue in fiscal 2025 against $409,657 for Medicinova (2.9 times as much). Longeveron grew faster (-49.9% against -59.0%). Longeveron kept more of each dollar of sales as profit: a net margin of -1893.6% against -2928.8%. Longeveron carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | LongeveronLGVN, 2025 | MedicinovaMNOV, 2025 |
|---|---|---|
| Revenue | $1.2m | $409,657 |
| Revenue growth | -49.9% | -59.0% |
| Net income | −$22.7m | −$12.0m |
| Operating margin | -1942.2% | -3242.5% |
| Net margin | -1893.6% | -2928.8% |
| Return on equity | -164.7% | -23.1% |
| Free cash flow | −$18.9m | −$9.8m |
| Cash | $4.7m | $30.8m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 37 | — |
| Market value | $55.5m | $70.9m |
| Price vs our value range | — | — |
| Moat score | 19 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 1 sales |